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Abstract We have generated transgenic mice, in either C57BLI 
6 or C3H background, expressing antisense glucokinase mRNA 
in fJ-cells. The glucose phosphorylating activity at 60 mM glucose 
in transgenic islets was significantly lower than that in controls, 
and the insulin secretory response to glucose was lower in trans-
genic islets than in those of controls in both strains. Following i.p. 
glucose challenge, higher blood glucose levels were observed in 
transgenic mice than in controls in the C57BL/6 but not the C3H 
background. These data suggest that a fJ-cell secretory defect, in 
combination with other undefined genetic factors, causes im-
paired glucose homeostasis in mice. 
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1. Introduction 
Non-insulin-dependent diabetes mellitus (NIDDM) is con-
sidered to be a heterogeneous and polygenic disorder. It is 
generally accepted that this disease is caused by a combination 
of insulin secretory defects and insulin resistance in insulin 
responsive organs. Several genetic defects have been identified 
in patients with NIDDM. One such defect is in glucokinase, an 
enzyme playing an important role in glucose metabolism in the 
liver and pancreatic fJ-cells [1-3]. Recently, fJ-cell secretory de-
fects were demonstrated in glucokinase-deficient diabetic pa-
tients [4], Therefore, this type of diabetes provides us with an 
important opportunity to study the effects of fJ-cell secretory 
defects on glucose homeostasis. To further study these effects, 
we have generated a murine model with reduced pancreatic 
fJ-cell glucokinase activity by expressing antisense glucokinase 
mRNA in fJ-cells. 
C57BLl6 mice were reported to be less glucose-tolerant than 
C3H mice [5]. In addition, it has been reported that a high-
calorie diet in animals with the C57BLl6 genetic background 
resulted in characteristics similar to those of human NIDDM 
[6]. We hypothesized that reduced glucokinase activity infJ-cells 
has different effects depending on the genetic background of 
the mice strains, Therefore, we backcrossed founder mice to 
both C57BLl6 and C3H strains. Our data indicate that a fJ-cell 
secretory defect causes impaired whole-body glucose homeo-
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stasis when combined with other, as yet to be identified, genetic 
factors in mice. 
2. Materials and methods 
2.1 Alllmals 
(C57BLl6 x DBA/2) Fl, C57BLl6 and C3H mice were purchased 
from Charles River Japan (Yokohama). A 268-bp mouse fi-cel1 gluco-
kinase cDNA fragment (-68 to 200, A of the start codon is denoted by 
+ 1) was amplified from polyA+ RNA of the murine fi-ce111me MIN6 
[7), and ligated under human insulin gene promoter as described prevI-
ously [8), in the antisense orientatIOn and micro-injected into fertilized 
eggs of (C57BLl6 x DBA/2) F2 mice We used only male mice for the 
analysis descnbed herein. Control mice were non-transgemc htter-
mates 
22. Northern blot analysis and RNase protectIOn assay 
Transgenic and non-transgenic islets were Isolated from 12- to 15-
week-old littermates by col1agenase infUSIOn through the bile duct. 
Total RNA was Isolated from murine tissues with an Isogen RNA 
extraction kit (Nippon Gene, Tokyo). For RNase protection assay, 
268-bp fi-cel1 glucokinase cDNA fragment described above was di-
gested with Sau3Al and a resulting 121-bp fragment was inserted into 
the EcoRI-BamHI site of pGEM4Z. The plasmid was hnearized at the 
EcoRI site and RNA probes were synthesized usmg the T7 RNA 
polymerase in the presence of [a-,2P)UTP 3 j.1g of islets total RNA was 
assayed using an RPA II kit (Ambion. TX). 
2.3. Glucose phosphorylatIOn activity 
Glucose phosphorylatmg activities m Islet homogenates were deter-
mined by fluorometry as descnbed previously [7). A 12,000 x g superna-
tant of homogenate, denved from - 200 Islets from one mouse, was used. 
2.4. 1nsul1ll secretIOn trom Isolated Islets 
Islets were Isolated from 14- to 18-week-old mice as described above. 
There was no apparent difference m islet size between control and 
transgemc mice. Batches of 10 islets were mcubated for 60 mm at 37"C 
in 300 j.1l of HEPES (10 mMl-balanced bicarbonate buffer supple-
mented with 0.5% BSA and varying concentrations of glucose in an 
atmosphere of95% 0, and 5% CO2, Immunoreactive msulm was meas-
ured by RIA. 
:2 5 Glucose tolerance test 
J.p glucose tolerance tests (2 mg/g wt glucose administered) were 
performed, after a 14-16-h fast, m 8-week-old mice. 
3. Results 
We obtained 15 transgenic founder mice which were then 
bred to the C3H strain. Northern blot analysis of the islets from 
Fl mice showed higher expression of antisense mRNA in two 
lines, termed GKrl5 and GKr38, than in other lines (data not 
shown). These lines were subsequently analysed. Blood glucose 
levels were determined at 2 h after cessation of free access to 
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Fig. I. Expression of antisense glucokIllase mRNA and reduced gluco-
kinase mRNA in isolated Islets. (A) 5)1g of total RNA from the isolated 
islets of a single mouse III C57BLl6 background were electrophoresed 
III 2.0% formaldehyde-agarose gel, transferred onto a nylon membrane, 
and probed with a murine ,B-cell glucokIllase cDNA fragment. Experi-
ments were performed 3x with similar results for both backgrounds. 
(B) RNase protectIOn assay was used to estimate the levels of glucoki-
nase mRNA in isolated islets from C57BLl6 background mice. The 
121-bp portion of T7-transcribed RNA was protected. Experiments 
were performed 2x with similar results for both backgrounds. 
the chow in the FI generation mice. Blood glucose levels were 
significantly elevated in transgenics as compared with those in 
non-transgenic littermates in lines GKrl5 (153 ± 26 vs. 
206 ± 15 mg/dl, mean ± S.D., n = 9) and GKr38 (167 ± 12 vs. 
202 ± II mg/dl, n = 4). The FI mice were then bred to the C3H 
strain. The differences in blood glucose levels between trans-
genic and non-transgenic littermates were minimal in this gen-
eration (data not shown). We speculated that the effects of 
antisense glucokinase mRNA expression were less evident in 
the C3H background. Therefore, the GKrl5 and 38 founder 
mice were bred to C57BLl6 mice. Ultimately, we obtained line 
GKrl5 and GKr38 animals which had been crossed with C3H 
or C57BLl6 strains for at least five generations. In the experi-
ments described bellow, we used the GKrl5 line which ex-
pressed more antisense GK mRNA than the GKr38 line. The 
GKr38 line yielded similar results (data not shown). 
Fig. IA shows Northern blot analysis of total RNA from 
pancreatic islets ofGKr15 transgenic and non-transgenic Iitter-
mates. An -600-bp band was hybridized with glucokinase 
cDNA probes. This size coincides with the expected size of the 
antisense glucokinase mRNA. Islets total RNA was also sub-
jected to RNase protection assay. An RNA fragment of 121 bp 
should be protected for the glucokinase mRNA. As shown in 
Fig. I B, the protected RNA amount was reduced in transgenic 
islets than in control islets, indicatmg a diminished expression 
of glucokinase mRNA in transgenic islets. 
Glucose phosphorylating activity at 0.6 or 60 mM glucose 
concentration was compared between islets from transgenic 
and non-transgenic mice (Fig. 2). Glucose phosphorylating ac-
tivity in transgenic islets was lower, by - 30%, than that of con-
trol islets at 60 mM glucose in both genetic backgrounds. How-
ever, the activity at 0.6 mM glucose did not differ between 
control and transgenic islets. The difference in glucose phos-
phorylating activities at these two glucose concentrations is 
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considered to be attributable to glucokinase activity. Therefore, 
we estimated the glucokinase activity in transgemc islets to be 
- 50% lower than that in control islets. 
Next, we studied glucose-stimulated insulin secretion from 
freshly isolated islets of control and transgenic mice. As shown 
in Fig. 3, insulin secretion from both C3H and C57BLl6 trans-
genic islets tended to be lower than that from control mice at 
10 and 25 mM glucose (P = -0.07) and significantly lower at 15 
mM glucose (P < 0.05). 
To examine the effects of this diminution in glucose-stimu-
lated insulin secretion from fJ-cells on whole-body glucose ho-
meostasis, we performed an i.p. glucose challenge test in these 
mice. As shown in Fig. 4, transgenic mice in the C57BLl6 
background had elevated blood glucose levels as compared 
with non-transgenic siblings at 45 and 90 min. In contrast, 
blood glucose levels did not differ between transgenic and non-
transgenic mice in the C3H background. 
To elucidate the mechanism underlying the different effects 
of impaired glucose-stimulated insulin secretion on glucose tol-
erance test in mice with the different genetic backgrounds, we 
assessed the expression of GLUT4 in skeletal muscle and that 
of hepatic glucokinase in these mice. The amount of GLUT4 
glucose transporter protein in skeletal muscle did not differ 
between these strains (data not shown). In contrast, as shown 
in Fig. 5, hepatic glucokinase mRNA levels in C57BLl6 mice 
were lower by - 50% than those in C3H mice, although there was 
no difference between control and transgenic tissues from mice 
with the same genetic background. 
4. Discussion 
Antisense glucokinase mRNA expression was used to make 
a fJ-cell glucokinase-deficient mice. Glucose phosphorylating 
activity and glucose-stimulated insulin secretion from trans-
genic islets were decreased as compared with those from control 
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Fig. 2. Glucose phosphorylatIllg activity in Islets from control (hatched 
column) and transgenic (shaded columns) mice in both the C57BLl6 
and the C3H strain. Glucose phosphorylating activity was measured at 
30°C at 0.6 or 60 mM glucose concentration. Values are mean ± S.D. 
of eight experiments. each performed in tnplicates. *Dlfference from 
control at P < 0 05. 
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Fig 3. Glucose-stimulated insulin secretIOn from Isolated Islets from 
control and transgenic mice In the C57BLl6 or the C3H background. 
Control (open circles) and transgemc (closed circles) Islets were Isolated 
in parallel. Batches of 10 islets were Incubated for 60 min at 37°C with 
varying concentratIOns of glucose. Values are mean ± S.D. of five or 
four expenments uSing mice in the C57BLl6 or the C3H background, 
respectively, each performed In triplicate. "Difference from control at 
P < 0 05. 
islets. These observations are consistent with glucokinase being 
the glucose-sensor molecule for glucose-stimulated insulin se-
cretion, as recently demonstrated by several investigators 
[9-11]. 
Another ,B-cell glucokinase-deficient mice were recently re-
ported, in which ,B-cell glucokinase activities were suppressed 
by expressIOn of glucokinase-targeted ribozyme [12]. The n-
bozyme-targeted mice had the C3H background and were re-
ported to exhibit no significant changes in whole-body glucose 
homeostasis, which is consistent with the results obtained with 
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our transgenic C3H background mice. The findings in both 
types of transgenic mice in the C3H background are different 
from those of human glucokinase-deficient patients, in whom 
glucose homeostasis impairment is mild but clinically signifi-
cant. The reasons for the differences are currently unclear. 
However, one possible explanation is that a glucokinase defi-
ciency outside of ,B-cells contributes significantly to the develop-
ment of the impaired whole-body glucose homeostasis. Gluco-
kinase is also expressed in hepatocytes, and glucokinase expres-
sion in pancreatic a-cells and certain neuroendocrine cell types 
has recently been reported [13]. The glucokinase expression 
outside of ,B-celis is presumably impaired in patients with a 
defect in the glucokinase gene, while that in our transgenic mice 
is likely to have remained normal. In this context, impaired 
glucagon secretion was recently documented in glucokinase-
deficient diabetic patients [14]. Thus, suppression of gluco-
kinase alone in,B-celis may not be sufficient for the deVelopment 
of Impaired glucose homeostasis in mice in the C3H back-
ground. 
In contrast to mice in the C3H background, we found that 
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Fig. 4. I.p glucose tolerance test In control (open circles) and transgemc 
(closed circles) mice in the C57BLl6 or the C3H background. Mice were 
fasted for 14-16 h and then given an l.p injectIOn of 2 mg of glucosefg 
of body weight. Blood samples were drawn at the Indicated time pOints 
from a tall vein Values are mean ± S D. of 12 transgenic and 9 control 
mice In the C57BLl6 background or 8 transgemc and 6 control mice In 
the C3H background. "Difference from control at P < 0 05. 
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Fig> 5. Expression of hepatic glucokinase 10 the C57BLl6 or C3H 
background mice. 20 j.lg of total RNA from the liver of control (C) and 
transgenic (T) mice were electrophoresed in a 1.0% formaldehyde-
agarose gel, transferred onto a nylon membrane. and probed with rat 
liver glucokinase cDNA fragment. Experiments were performed 3x 
us10g different ammals with similar results. 
transgenic C57BLl6 background mice exhibited impaired glu-
cose homeostasis. We speculated that as yet unknown genetic 
factors in the C57BLl6 strain, which differ from those in the 
C3H strain, had different effects on glucose metabolism in vivo, 
even though glucose-stimulated insulin secretion was impaired 
in transgenic mice of both strains. Several differences have been 
reported between C57BLl6 and C3H strains [5,15.16]. The C3H 
strain has been reported to be one of the strains with the highest 
hepatic glucokinase activity [17]. We found that hepatic gluco-
kinase mRNA levels were lower in C57BLl6 mice than in C3H 
mice. Reduced activity of glucokinase in liver would result in 
diminished hepatic glucose uptake. Although a decrease in in-
sulin secretion due to reduced ,B-cell glucokinase activity is 
likely to cause an insufficient suppression of hepatic glu-
coneogenesis and glycogenolysis in transgenic mice of both 
strains, this impaired suppression would result in greater dete-
rioration of glucose metabolism in the liver with a lower glucose 
uptake. ThiS might account for transgenic mice in the C57BLl6 
but not C3H background exhibiting impairment in whole-body 
glucose homeostasis. Sufficient expression of hepatic gluco-
kinase could mask a reduced suppressive effect on hepatic glu-
cose production, caused by impaired insulin secretIOn, in trans-
genic C3H background mice. Although it is not clear whether 
the lower hepatic glucokinase is the only factor to render 
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C57BLl6 strain more sensitive to the inhibition of ,B-cell gluco-
kinase expression, this finding suggests that' hepatic gluco-
kinase expression is one factor contributing to the regulation 
of whole- body glucose homeostasis. Nonetheless, our results, 
obtained in mice in different genetic backgrounds, demonstrate 
that a,B-cell secretory defect leads to impairment of whole-body 
glucose homeostasis when combined with other unknown ge-
netic factors. 
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